Receptor oligomerization and beyond: a case study in bone morphogenetic proteins

Kai Heinecke1, Axel Seher, Werner Schmitz

  • 1Physiologische Chemie II, Biozentrum, Universität Würzburg, Würzburg, Germany. kai.heinecke@biozentrum.uni-wuerzburg.de

BMC Biology
|September 9, 2009
PubMed
Abstract

Insights

Transforming growth factor-beta (TGF-β) superfamily ligands exhibit promiscuous binding to type I and type II receptors. This study reveals how ligand-receptor interactions, influenced by binding affinity and stoichiometry, generate diverse cellular signals despite limited receptor availability.

Area of Science:

  • Cellular signaling
  • Molecular biology
  • Biochemistry

Background:

  • Transforming growth factor-beta (TGF-β) superfamily ligands signal through type I and type II serine/threonine kinase receptors.
  • Mammalian cells express a limited number of TGF-β receptors (7 type I, 5 type II) relative to the numerous ligands, suggesting significant ligand-receptor promiscuity.
  • Variations in binding affinities and specificities are crucial for generating distinct signaling outcomes from ligand-receptor complexes.

Purpose of the Study:

  • To investigate the binding kinetics and specificity of ligand-receptor interactions within the TGF-β superfamily.
  • To elucidate how different binding affinities and receptor stoichiometries contribute to distinct cellular responses.
  • To understand signal generation in a receptor-limited system characterized by ligand-receptor promiscuity.

Main Methods:

  • In vitro interaction analyses to determine binding kinetics (e.g., 'slow on/slow off', 'fast on/fast off').
  • Avidity studies using immobilized receptors to assess cooperative binding of dimeric ligands.
  • In vivo binding studies on whole cells using homodimeric and heterodimeric bone morphogenetic protein 2 (BMP2) mutants to identify binding sites and affinities.

Main Results:

  • Two binding kinetic prototypes were observed: 'slow on/slow off' and 'fast on/fast off'.
  • Ligand binding specificity to receptors of a single subtype was only moderate, with bivalent interactions contributing to avidity.
  • In vivo studies identified low and high affinity binding sites for BMP2, correlating with the presence of one or two BMP receptor (BMPR)-IA chains, respectively.
  • High affinity sites mediated rapid, transient responses at low ligand concentrations, while low affinity sites supported sustained signaling at higher concentrations.

Conclusions:

  • Ligand binding to a high-affinity receptor chain initiates signaling complex formation, enabling subsequent recruitment of other receptor subtypes.
  • Receptor complexes can comprise up to four receptors, consistent with observed low ligand-receptor specificity within subtypes.
  • Heterooligomeric signaling complexes with a single type I receptor chain are possible for BMP2, adding complexity.
  • Despite ligand-receptor promiscuity, a diverse range of signals can be generated within this receptor-limited system.

Related Concept Videos

Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: